Rinvoq® (Upadacitinib) 在类风湿性关节炎患者中,与首次使用 TNF 抑制剂失败的患者进行的对照研究中,显示出其在主要终点上的优越性,超越了 Humira® (Adalimumab)。
Rinvoq® (Upadacitinib) 在类风湿性关节炎患者中,与首次使用 TNF 抑制剂失败的患者进行的对照研究中,显示出其在主要终点上的优越性,超越了 Humira® (Adalimumab)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.